Adicet Bio Shares Insights at Gene and Cell Therapy Meeting
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Institutions Along With Retail Investors Who Hold Considerable Shares InAdicet Bio, Inc. (NASDAQ:ACET) Come Under Pressure; Lose 29% of Holdings Value
Key Insights The considerable ownership by retail investors in Adicet Bio indicates that they collectively have a greater say in management and business strategy The top 8 shareholders own 51% of th
Wedbush: Reiterates the Adicet Bio (ACET.US) rating and adjusted from superior to superior market rating, with a target price of $5.00.
Wedbush: Reiterates the Adicet Bio (ACET.US) rating and adjusted from superior to superior market rating, with a target price of $5.00.
Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target
Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:ACET) with a Outperform and maintains $5 price target.
Adicet Bio Showcases Promising ADI-270 Cancer Therapy Data
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
Adicet Bio Is Maintained at Buy by HC Wainwright & Co.
Adicet Bio Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Adicet Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Edward White maintains Adicet Bio with a Buy and maintains $10 price target.
Analysts Offer Insights on Healthcare Companies: Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX)
Adicet Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio To Present At H.C. Wainwright Cell Therapy Virtual Conference; Webcast 10:30 AM ET
Adicet Bio May Offer And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $100M From Time To Time
Adicet Bio May Offer And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $100M From Time To Time
BGFV, STI and HNST Are Among After Hour Movers
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?
Adicet Bio Inc (ACET) Reports Q4 and Full Year 2023 Financial Results
Adicet Bio: A Strong Buy on Robust Financials and Promising Clinical Trials
Buy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial Footing
Adicet Bio Price Target Maintained With a $5.00/Share by Wedbush
Adicet Bio Price Target Maintained With a $5.00/Share by Wedbush
No Data